Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

Lexicon (LXRX) announced The Lancet Diabetes & Endocrinology has published a research paper analyzing the ability of sotagliflozin, a dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio ...

R. China, Zhengzhou, Henan Province, China; qqyyiillyy{at}126.com Objectives The protective role of sodium glucose cotransporter 2 (SGLT2) inhibitors in renal outcomes has been revealed by large ...

The Last of Us season 2 is slowly taking shape ahead of its release this year. After a couple of trailer drops and plenty of details about the plot and the characters, we can tell it's going to be ...

They added that “it seems very likely that SGLT2 inhibitors will also result in a substantial reduction in recurrent stone events in patients with pure [calcium oxalate] stones.” Despite the concern ...

Objective The association between the regular use of proton pump inhibitors (PPIs) and the risk of type 2 diabetes remains unclear, although a recent randomised controlled trial showed a trend towards ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

Hypertension is a major global health issue. Aldosterone synthase inhibitors (ASIs) have emerged as a promising therapeutic strategy for blood pressure control. A thorough search of the MEDLINE and ...